Brought to you by 
Octapharma gets recombinant technology, minority stake in Glycotope
01 Feb 2023
Executive Summary
Glycotope GMBH licensed Octapharma AG exclusive global rights to its recombinant technology GlycoExpress (GEX) cell line plus research, development, and commercialization rights to its preclinical Factor VII GEX blood coagulant candidates for hemophilia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Octapharma gets recombinant technology, minority stake in Glycotope
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice